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Context: Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teen-
agers in Europe and theUnited States, has been associatedwith impairedbonemineral acquisition
during adolescence and accelerated bone loss in later life. Studies on the association between
DMPA use and fracture risk are limited.
Objective: We aimed at evaluating the relationship between use of hormonal contraceptives,
specifically DMPA, and fracture risk.
Design: We conducted a case-control analysis using the United Kingdom-based General Practice
Research Database.
Setting and Participants: Participants were females aged 20–44 yr with an incident fracture di-
agnosis between 1995 and 2008.
Main OutcomeMeasures:Odds ratios (OR) with 95% confidence intervals (CI) of incident fracture
in relation to exposure toDMPAor combinedoral contraceptiveswere assessed.Adjustmentswere
made for smoking, body mass index, and additional potential confounders.
Results:We identified 17,527 incident fracture cases and 70,130 control patients (DMPA exposure: 11
and 8%, respectively). Comparedwith nonuse, current use of one to two, three to nine, or 10 ormore
DMPA prescriptions yielded adjusted OR for fractures of 1.18 (95% CI  0.93–1.49), 1.36 (95% CI 
1.15–1.60),and1.54 (95%CI1.33–1.78), respectively.Fractureriskwashighestafter longertreatment
duration (2–3yr), and therewasnodifference inpatients belowandabove theageof30 yr. Forusers
of combined estrogen-containing oral contraceptives, the OR were around 1.
Conclusions: This population-based study suggests that use of DMPA is associated with a slightly
increased risk of fractures. (J Clin Endocrinol Metab 95: 4909–4916, 2010)
Exposure to sex hormones during puberty plays an im-portant role in the accrual of bone mass, and sus-
tained production of estrogens is required for the main-
tenance of bone mass in adult women (1). Low estrogen
levels are seen in women using depot medroxyprogester-
one acetate (DMPA) for contraception, a long-acting pro-
gestin-only contraceptive, administered by 3-monthly im
injection (2).DMPAisusedbymore than9millionwomen
worldwide and has a high usage in the United Kingdom
and the United States (3). The contraceptive action of
DMPA results from its suppression of gonadotropin se-
cretionwhich in turn inhibits ovarian estradiol production
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and prevents ovarian follicularmaturation and ovulation.
By one year of use, most women become amenorrheic (4),
and there has been concern over potential negative effects
on bone (5).
In contrast to estrogen-containing oral contraceptives,
which do not appear to have negative effects on biochem-
ical markers of bone turnover or bone mineral density
(BMD) (6), use of DMPA has been associated with accel-
eratedbone turnover (7–10) andwith adecline inBMD(3,
7, 11–18). Cross-sectional studies have described BMD
deficits ranging from 2.5–18% at the lumbar spine and
from 2.2–17% at the proximal femur (18). Furthermore,
longitudinal studies in adult women have demonstrated
accelerated bone loss in new DMPA users (19–21) with
loss at the lumbar spine of up to 5.8% after 2 yr (21).
Whether DMPA influences fracture risk cannot be de-
termined from existing literature because studies investi-
gating the association between DMPA use and fracture
risk are limited (6). A few case reports have suggested an
association between DMPA use and fractures in adult
women (22, 23), as did three observational studies (24–
26). However, these studies had important limitations,
such as low number of DMPAusers or limited availability
of potential confounders. Of note, bone loss occurring
with DMPA use may be reversible with gain in BMD after
discontinuation of DMPA (17, 19, 27). Therefore, the
question remainswhether past use ofDMPAaffects future
fracture risk.
Given that use of DMPA is common and that its indi-
cation may expand due to its contraceptive efficacy and
increasing use in women with bleeding disorders, it is im-
portant to learn more about potential deleterious effect of
DMPAonskeletalhealth. In this largepopulation-based study,
weexploredtheassociationbetweenuseofDMPAorcombined
oral contraceptives and the risk of incident fracture.
Materials and Methods
We conducted a matched case-control analysis of the risk of
having a first-time fracture in relation to current or previous use
of DMPA, low-dose MPA alone, or estrogen containing oral
contraceptives within the United Kingdom-based General Prac-
tice Research Database (GPRD).
Data source
Data were derived from the United Kingdom-based GPRD,
which has been described previously (28, 29). Briefly, this data-
base was established around 1987 and contains information on
more than 5 million patients, of whom about 3 million are cur-
rently registered, and a cumulative follow-up time of more than
32 million person-years. The patients enrolled in the GPRD are
representative of the United Kingdom with regard to age, sex,
geographic distribution, and annual turnover rate.General prac-
titioners (GP) have been trained to record medical information
including demographic data, medical diagnoses, hospitaliza-
tions, deaths, and drug prescriptions using standard software
and standard coding systems. The GP generate prescriptions di-
rectly with the computer, and this information is automatically
transcribed into the computer record. It contains the name of the
preparation, route of administration, dose, and number of tab-
lets for each prescription. The recorded information on drug
exposure and diagnoses has been validated and proven to be of
high quality (30, 31). The GPRD has been the source of many
observational studies, including research on fractures (32–35).
Based on previous record reviews by ourselves (32) and others
(35), we have determined that the diagnosis of fracture in the
GPRD is very accurate, with a confirmed proportion of at least
90% after comparing computer-recorded diagnoses with hospi-
tal discharge letters and/or questionnaire information provided
by GP. The study was approved by the Independent Scientific
Advisory Committee for Medicines and Healthcare Products
Regulatory Agency database research.
Study population: case and control definition
We identified via Oxford Medical Information System and
Read codes all females between 20 and 44 yr of age with a first-
time fracture diagnosis (including vertebral and nonvertebral
fractures) between 1995 and 2008. All fractures were clinically
diagnosed. We excluded patients with less than 3 yr of active
history in the database before the first-time diagnosis of frac-
ture (index date), and we also excluded cases with a diagnosis
of cancer, Paget’s disease, osteoporosis, osteomalacia, alco-
holism, HIV, or use of anti-osteoporotic drugs (i.e. bisphos-
phonates, teriparatide, calcitriol, and raloxifen) before the
index date.
From the base population, we identified at random four con-
trol subjects per fracture case, matched on calendar time (same
index date), age (same year of birth), sex, general practice, and
years of history in the GPRD. We applied the same exclusion
criteria to controls as to case patients.
Exposure to DMPA and other hormones
For each case and control, we assessed from the computer
record the exposure history for DMPA, low-doseMPA alone, or
combined oral contraceptives before the index date. Patients
were classified as current users if the last prescription for a study
drug of interest was recorded less than 180 d or as past users if
it was recorded 180 or more days before the index date. We also
classified users by durationof use before the indexdate, using the
number of prescriptions as proxy (one to two, three to nine, or
10 for DMPA and for oral contraceptives, or one to two or
three or more for MPA low dose), and we further combined
duration and timing of use into one variable (i.e.we created user
categories of current use of one to two, three to nine, or 10
prescriptions and past use of one to two, three to nine, or 10
prescriptions). For the main analysis, we created a model in
which subsequent or concurrent use of various hormonal con-
traceptive drugs before the index date was possible, and we ad-
justed for such overlapping use in the multivariate model.
Statistical analysis
We conducted conditional logistic regression analyses using
the SAS statistical software (version 9.1; SAS Institute, Cary,
NC). We displayed relative risk estimates as odds ratios (OR)
with 95% confidence intervals (CI). We adjusted OR for the
4910 Meier et al. DMPA and Fracture Risk J Clin Endocrinol Metab, November 2010, 95(11):4909–4916
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 February 2014. at 07:52 For personal use only. No other uses without permission. . All rights reserved.
potential confounders age, sex, general practice, calendar time,
and years of recorded history in the database by matching, and
for smoking status (non, current, ex, or unknown) and body
mass index (BMI) (18.5, 18.5–24.9, 25.0–29.9, and 30 kg/
m2, or unknown) in the multivariate model. The risk estimates
were further adjusted for a recorded history of asthma, epilepsy,
use of -blockers, proton pump inhibitors, and anticonvulsants
[all combined by timing (currentmeans90 d before index date;
past means thereafter) and duration (one to nine or 10 pre-
scriptions)]; systemic corticosteroids, benzodiazepines, and se-
rotonin reuptake inhibitors [all combined by timing (currentme-
nas90dbefore indexdate; pastmeans thereafter) andduration
(one to four or five ormore prescriptions)]; and progestins (same
classification as for DMPA).
Potential confounding by a number of other variables was
further tested in univariate analyses with the log likelihood ratio
test, but they were not included in the final model because they
did not materially change the main effect measure.
ToevaluatewhethermissinginformationonexposuretoDPMA
obtained bywomen from family planning clinics (FPC)wouldma-
terially affect our results, we conducted a number of sensitivity
analyses.Firstweexcludedwomenfromtheanalysiswhomayhave
received DPMA exclusively via FPC. We compared longer-term
DPMA use with short-term DPMA use and assessed the relative
fracture risk; thus, this analysis was restricted to womenwho used
DMPA obtained through the GP. It is still possible that the short-
term user group also contained some women who were actually
long-termDMPAusers, if for examplemostDMPAusewas issued
by a FPC and the GP noted only one prescription in the record. To
evaluate this possibility, we classified women with only one re-
cordedDMPAprescription in a separate group in another analysis.
Thenwe conducted another analysis in a subgroup of womenwho
most likely receivedall of theirDMPAprescriptions fromtheGPby
excluding all women who had any evidence in their records of at-
tending a FPC. Because we were mainly interested in low-trauma
fractures, we also conducted another sensitivity analysis in women
who did not have any evidence for an accident recorded before the
indexdate.Althoughweexcludedpatientswithalcohol abuse from
ourstudy,weexplored the impactof socialalcoholconsumptionon
the relative fracture risk. We categorized patients into current,
former,ornoalcohol consumption (orunknown),andwestratified
those with recorded current alcohol consumption into fewer than
eight, eight to 14, 15–42, 43–63, 64 ormore, or unknownnumber
of units per week. Because nonusers of contraceptives may be dif-
ferent from users, we compared exclusive DMPAusers with exclu-
sive users of other hormonal contraceptives instead of nonusers of
DMPA. Finally, we restricted our analysis to patients who had a
fracture potentially related to osteoporosis, i.e. to patients with
spine, hip, wrist, or humerus fractures.
Results
We identified 17,527 female case patientswith an incident
fracture diagnosis and 70,130 matched control women.
The mean number of years for cases and controls before
the index date was around 9 yr. Table 1 shows the type of
clinically diagnosed fractures.
The age distribution and the prevalence of relevant co-
morbidities of cases and controls are displayed in Table 2.
Of the 17,527 fracture cases and their 70,130 controls,
1913 (11%) and 5715 (8%), respectively, had some
DMPA use recorded. The OR of developing a fracture in
association with current use of one to two, three to nine,
or 10 or more DMPA prescriptions, compared with non-
use of DMPA and adjusted for BMI, smoking, comorbidi-
ties and comedication, were 1.18 (95% CI 0.93–1.49),
1.36 (95% CI  1.15–1.60), and 1.54 (95% CI  1.33–
1.78), respectively. The adjusted OR of developing a frac-
ture for past use of one to two, three to nine, or 10 ormore
DMPA prescriptions were 1.17 (95% CI  1.07–1.29),
1.23 (95% CI  1.11–1.36), and 1.30 (95% CI  1.09–
1.55), respectively (Table 3). We additionally used a dif-
ferent cutoff for past use (i.e. 720 d), and the OR for
current and past use of DMPA were 1.03 (95% CI 
0.88–1.22), 1.38 (95% CI 1.22–1.55), and 1.52 (95%
CI  1.34–1.72) for current use and 1.24 (95% CI 
1.11–1.37), 1.17 (95% CI  1.03–1.32), and 1.17 (95%
CI  0.92–1.49) for past use, for the various levels of
exposure duration.
We then stratified the groupof currentDMPAusers of 10
or more DMPA prescriptions by age and fracture type. An
increased fracture risk inassociationwithcurrentDMPAuse
was seen in patients below and above the age of 30 yr. For
patients above 30 yr of age, past use of 10 or more DMPA
prescriptions also yielded an increased relative risk. The risk
of all types of fractures tended to be increased with current
long-term exposure to DMPA (Table 4).
Low-dose MPA (data not shown) and estrogen-con-
taining hormonal contraceptives did not affect the relative
fracture risk (Table 3).
As mentioned above, we conducted a number of sen-
sitivity analyses. In the analyses that we conducted to re-
duce potential exposure misclassification, we found OR
TABLE 1. Type of fractures
Fracture site
No.
(n  17,527) %
Spine 285 1.6
Hip, femur, patella 355 2.0
Hip 62 0.3
Femur, patella 293 1.7
Lower leg 2808 16.0
Foot (including toes) 4234 24.2
Toes 2072 11.8
Calcaneus 100 0.6
Clavicle 496 2.8
Humerus, elbow 1020 5.8
Forearm (including wrist) 2859 16.3
Hand (including fingers) 4261 24.3
Fingers 1911 10.9
Rib 789 4.5
Not specified 420 2.4
Osteoporotic fractures
(spine, hip, wrist, humerus)
1936 11.0
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around 1.25 regardless of the definition of short-term use
(patientswith one to twoDMPAprescriptions, or patients
with one or two to three DMPA prescriptions separated).
In women who had no FPC attendance recorded, the OR
for current use of 10 or more DMPA prescriptions, as
compared with nonuse, was 1.58 (95%CI 1.36–1.83).
The OR for current users of 10 or more DMPA prescrip-
tions vs. nonusers was 1.59 (95% CI  1.36–1.85) in an
analysis restricted to cases without any evidence for an
accident-related fracture before the index date.
Compared with patients who consumed no alcohol,
increasinguseof alcoholwasassociatedwithan increasing
TABLE 2. Characteristics of case patients with fractures and matched controls
Variable
No. of cases
(n  17,527) %
No. of controls
(n  70,130) %
OR adjusteda
(95% CI)
Age group (yr)b
20–29 5745 32.8 22,959 32.6
30–39 7533 43.0 30,165 43.0
40–44 4249 24.2 17,006 24.3
Smoking status
Nonsmoker 8532 48.7 37,479 53.4 Reference
Current smoker 5336 30.4 17,888 25.5 1.25 (1.20–1.30)
Ex-smoker 1841 10.5 6870 9.8 1.13 (1.07–1.20)
Unknown 1818 10.4 7893 11.3 1.00 (0.92–1.07)
BMI (kg/m2)
12–18.4 511 2.9 2165 3.1 0.96 (0.87–1.07)
18.5–24.9 7513 42.9 31,976 45.6 Reference
25–29.9 3526 20.1 13,113 18.7 1.13 (1.08–1.18)
30–60 2582 14.7 8757 12.5 1.20 (1.14–1.27)
Unknown 3395 19.4 14,119 20.1 1.05 (1.00–1.11)
Comorbidities
Asthma 3234 18.5 10,500 15.0 1.16 (1.11–1.22)
Epilepsy 416 2.4 1109 1.6 1.16 (0.99–1.35)
a Adjusted for all covariates listed in the table plus use of -blockers, proton pump inhibitors, systemic corticosteroids, benzodiazepines, serotonin
reuptake inhibitors, and anticonvulsants.
b Matching variables.
TABLE 3. Exposure to DMPA and other hormonal contraceptives and relative risk of fracture
Exposure, no. of
prescriptions
No. of cases
(n  17,527) %
No. of
controls
(n  70,130) %
Unadjusted ORa
(95% CI)
Adjusted ORb
(95% CI)
DMPA
Nonuse 15,614 89.1 64,415 91.9 Reference Reference
Current
1–2 93 0.5 305 0.4 1.27 (1.01–1.61) 1.18 (0.93–1.49)
3–9 209 1.2 573 0.8 1.52 (1.30–1.79) 1.36 (1.15–1.60)
10 280 1.6 710 1.0 1.67 (1.45–1.92) 1.54 (1.33–1.78)
Past
1–2 620 3.5 1985 2.8 1.31 (1.19–1.44) 1.17 (1.07–1.29)
3–9 529 3.0 1609 2.3 1.38 (1.25–1.53) 1.23 (1.11–1.36)
10 182 1.0 533 0.8 1.45 (1.22–1.72) 1.30 (1.09–1.55)
Hormonal contraception
(estrogen-containing)
Nonuse 6591 37.6 26,578 37.9 Reference Reference
Current
1–2 215 1.2 871 1.2 0.99 (0.85–1.16) 1.01 (0.87–1.18)
3–9 1136 6.5 4696 6.7 0.98 (0.91–1.05) 1.01 (0.94–1.09)
10 2327 13.3 9073 12.9 1.04 (0.98–1.10) 1.09 (1.03–1.16)
Past
1–2 1972 11.3 7820 11.2 1.02 (0.96–1.08) 1.00 (0.95–1.07)
3–9 3178 18.1 12,787 18.2 1.01 (0.96–1.06) 0.99 (0.94–1.04)
10 2108 12.0 8305 11.8 1.03 (0.97–1.10) 1.03 (0.97–1.10)
a Adjusted for age, general practice, calendar time, and history in the database by matching.
b Adjusted for BMI, smoking, asthma, epilepsy, use of progestins (single preparations), MPA low dose, -blockers, proton pump inhibitors,
systemic corticosteroids, benzodiazepines, serotonin reuptake inhibitors, anticonvulsants, and contraceptive not under investigation.
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risk of fracture. The OR of developing a fracture for pa-
tientswho consumed fewer than eight, eight to 14, 15–42,
43–63, or 64ormore units perweekwere 1.07 (95%CI
1.02–1.14), 1.29 (95%CI 1.20–1.39), 1.62 (95%CI
1.46–1.79), 1.81 (95% CI 1.11–2.96), and 2.41 (95%
CI  1.19–4.85), respectively. However, adjustment for
alcohol consumption did not change the association be-
tween DMPA use and fracture.
A direct comparison of users of 10 or more prescrip-
tions of DMPA with users of 10 or more prescriptions of
other hormonal contraceptives yielded an OR of 1.46
(95%CI 1.15–1.85). Finally, when we considered only
patients with fractures potentially related to osteoporosis
(n 1936), the OR for users of 10 or more prescriptions
ofDMPA to develop a fracturewas 1.49 (95%CI 0.97–
2.28) compared with nonusers of DMPA.
Discussion
Cross-sectional (3, 7, 11–18) and longitudinal (19–21)
studies have indicated that the use of DMPA may have
adverse effects on bone metabolism, resulting in impaired
bone mineral acquisition during adolescence and acceler-
ated bone loss in adult life. The findings of this large,
population-based case-control analysis provide further
evidence that current or past use of DMPA may be asso-
ciated with an increased risk of fractures in women be-
tween the age of 20 and the perimenopausal period. The
relative fracture riskwasmainly increased forwomenwith
current exposure of more than 2–3 yr. We also observed
a slightly increased risk after past exposure of 10 or more
DMPA prescriptions, mainly in women above the age of
30. When we used another cutoff for past exposure to
DMPA (i.e.720 d instead of180 d), the increased risk
for past exposure to DMPA largely disappeared, which
may indicate that the effect of DMPAon fracture riskmay
be reversible after some time after stopping the medica-
tion. The fracture risk was independent of BMI, smoking
habits, comorbidities, and comedication including use of
other contraceptives and hormonal treatments.
Data on the association between DMPA use and frac-
ture risk are limited. In a survey of administrative records
of medications and fractures in 6773 women with devel-
opmental disabilities, DMPA use was related to fractures
TABLE 4. Use of DPMA and relative risk of fracture, stratified by fracture type and agea
Characteristics
Cases Controls
OR 95% CI P valuen % n %
Current use of 10 DMPA
prescriptions by type of
fracture
Spine 5 1.8 12 1.1 1.88 0.58–6.06 0.2922
Hip, femur, patella 5 1.4 15 1.1 1.36 0.45–4.11 0.5819
Hip 0 0.0 3 1.2 NA NA NA
Femur, patella 5 1.7 12 1.0 1.77 0.56–5.56 0.3274
Lower leg 44 1.6 107 1.0 1.56 1.08–2.27 0.0185
Foot 67 1.6 165 1.0 1.62 1.20–2.18 0.0015
Calcaneus 1 1.0 3 0.8 1.22 0.07–20.79 0.8913
Toes 31 1.5 82 1.0 1.53 0.99–2.37 0.0543
Forearm 42 1.5 125 1.1 1.35 0.94–1.93 0.1068
Clavicle 7 1.4 25 1.3 1.19 0.49–2.91 0.7035
Hand 77 1.8 182 1.1 1.55 1.17–2.05 0.0022
Fingers 28 1.5 81 1.1 1.28 0.81–2.01 0.2936
Humerus, elbow 19 1.9 48 1.2 1.56 0.89–2.74 0.1237
Rib 12 1.5 26 0.8 1.95 0.89–4.28 0.0950
Osteoporotic fractures
(spine, hip, wrist, humerus)
31 1.6 87 1.1 1.49 0.97–2.28 0.0671
Current and past use of 10
DMPA prescriptions by
age (yr)
30, current use 100 1.7 258 1.1 1.54 1.21–1.96 0.0005
30–44, current use 180 1.5 452 1.0 1.56 1.31–1.87 0.0001
30, past use 43 0.8 169 0.7 0.97 0.69–1.37 0.8553
30–44, past use 139 1.2 364 0.8 1.46 1.19–1.79 0.0002
NA, Not applicable.
a Adjusted for age, general practice, calendar time, and history in the database by matching and for BMI, smoking, asthma, epilepsy, use of
progestins (single preparations), MPA low dose, -blockers, proton pump inhibitors, systemic corticosteroids, benzodiazepines, serotonin reuptake
inhibitors, anticonvulsants, and other oral contraceptives.
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(OR  2.4; 95% CI  1.3–4.4) (24). Lappe et al. (25)
found an increased risk of stress fractures among non-
Hispanic White female army recruits with a history of
DMPA use who were completing basic training (relative
risk  1.7; 95% CI  1.0–2.9; P  0.04). Of note, these
reports are not necessarily representative of the entire fe-
male population, becausewomenwith developmental dis-
orders may be more likely to have epilepsy-related frac-
tures (36), and stress fractures are a greater hazard for
army recruits than for the general population. Recently,
the authors of a Danish case-control study reported an
increased risk of fractures in DMPA users compared with
nonusers (OR  1.44; 95% CI  1.01–2.06); however,
the interpretation of the study findings is limited due to a
low number of DMPA users and limited availability of
potential confounders (26). In our study involving a larger
group of exposedwomen (8.7%),we observed an increas-
ing relative fracture risk associatedwith increasingDMPA
exposure duration, with the highest risk in users of 10 or
more recorded DMPA prescriptions corresponding to
more than 2–3 yr, independent of the timing of exposure.
Whenwe stratified the results by age (30and30yr),
the association between current use and fracture risk was
seen in both age strata. Past use was associated with an
increased fracture risk only in women between 30 and 44
yrof agebutnot in youngerwomen.These findings remain
unclear specifically because duration of DMPA exposure
in both age strata has been similar.Onemight hypothesize
that despite the fact that discontinuation of DMPA use
may restore bone loss (17, 19, 27), this process may take
longer in women of more advanced age.
When we stratified by fracture type, we observed in-
creased fracture risks for longerDMPAusersparticularly for
nonvertebral fractures, specifically lower extremity frac-
tures (mainly foot fractures) and hand and humerus frac-
tures.Therewas also a tendency toward increased fracture
risks for other types of fractures. Although the types of
fractures that we included in our analysis were mainly
low-trauma fractures, we additionally restricted our anal-
ysis to patients who did not have any evidence for an ac-
cident in their records before the index date and found an
OR that was closely similar to the overall relative risk.
Nevertheless, because fractures observed in women be-
tween 20 and 44 yr of age were not typically related to
metabolic bone disease, we cannot rule out severe trauma
as a proximal cause for some fractures. Whether these
fractures are the result of DMPA-associated increased
bone turnover remains contentious. Finally, we ran an
analysis restricted to patients with fractures potentially
related to osteoporosis; the adjustedOR for users of 10 or
more DMPA prescriptions was 1.49 (95% CI  0.97–
2.28) compared with nonusers of DMPA.
As depicted in Table 2, we observed an increased frac-
ture risk inwomenwith a BMI above 25 kg/m2.However,
in a former analysis inwhichwe had included alsowomen
above the age of 50,weobserved an increased fracture risk
for patients with a BMI below 18.5 kg/m2, whereas for
patients with a BMI above 25 kg/m2, there was a slightly
decreased fracture risk (data not shown). For patients be-
low the age of 50 (or below the age of 45, as in our study
population), this could not be observed. Our findings are
in line with a recent metaanalysis evaluating BMI as a
predictor of fracture risk (37), which reported that the
gradient of risk per unit of BMI increased with advancing
age, predominantly after 55 yr of age, without adjustment
for BMD.
Several studies investigated the effect of combined oral
contraceptives on BMD, but none included fractures as an
outcome. Combined oral contraceptives do not appear to
affect bonemassorbone turnover as a result ofmaintained
estrogen exposure (6, 38). In accordance with these data,
wedidnotobserveaneffecton fracture risk inwomenwith
current or past use of estrogen-containing oral contracep-
tives. A direct comparison of women using 10 or more
DMPA prescriptions with users of combined oral contra-
ceptives yielded an adjusted OR of 1.46 (95% CI 
1.15–1.85).
In the United Kingdom, FPC can also prescribe hor-
monal contraceptives to women, which may lead to ex-
posure misclassification in the GPRD. If exposure is
missed at random (i.e. about the same proportion is af-
fected in cases and controls), the estimatedORwould tend
toward the null. According to a report of the Office for
National Statistics in the United Kingdom, more than
82% of the women who used Family Planning Services
had also seen their own GP or a practice nurse. Further-
more, a large proportion of women who attended FPC
werebelow the ageof 20yr, andwedidnot include this age
group in our analysis (39). The authors of a previous
GPRD-based study explored use of hormonal contracep-
tion among diabetic women and concluded that recording
of hormonal methods was at a high level when compared
withofficialUnitedKingdomstatistics; therewas evidence
only for low recording of nonhormonal contraceptive
methods (40). However, to further address the issue of
exposure misclassification in our study population, we
conducted a number of sensitivity analyses that all re-
sulted in similar findings of a slightly increased OR of
around 1.25.
Aside from potential exposure misclassification, addi-
tional potential limitations of our study need to be dis-
cussed. First,we cannot exclude thepossibility that a small
proportion of fractures may have been missed or misclas-
sified. Systematic radiographic screenings to identify
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asymptomatic vertebral deformities and fractures are not
available; consequently, the number of vertebral fractures
may be underestimated. Second, it is possible that certain
demographic or lifestyle factors, such as socioeconomic
status, dietary habits, and physical activity, are associated
with fracture risk and with use of DMPA and that we did
not fully control for potential confounding by such pa-
rameters. This is of special interest because it has been
reported that DMPA users are less likely to be educated
beyond 16 yr andmore likely to have a low calcium intake
and to become pregnant at a younger age and more fre-
quently than their peers, all ofwhichmayhave an effect on
bone health (15, 20–21, 41). To control for socioeco-
nomic status as much as possible, case patients and con-
trols were matched on general practice. Furthermore, we
comparedDMPAusersof longerdurationwith short-term
DMPAusers,whichyieldedan increased fracture riskwith
long exposure duration of DMPA, which would not be
expected if the increased fracture risk was due only to
residual confounding by socioeconomic or lifestyle
factors.
In summary, this large population-based case-control
study provides additional evidence that the use of DMPA
of approximately 2 ormore yearsmay slightly increase the
risk of fractures.
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